This content is machine translated HSP90 inhibition A new therapeutic approach for breast cancer In an initial phase II study in metastatic breast cancer, the HSP90 inhibitor ganetespib has shown promising antitumor activity in HER2-positive and triple-negative breast cancer (TNBC). Due to the favorable…
